Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- Finding moments that transcend the grief of ALS
- Enrollment complete in Phase 2b trial of add-on therapy for adults with ALS
- ALS Nexus 2026: Event spotlights care advances, community goals
- ALS didn’t end my story — it helped me discover my purpose
- Predisease pollution exposure may worsen survival in ALS, study says